To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD - Trial NCT05535972
Access comprehensive clinical trial information for NCT05535972 through Pure Global AI's free database. This Phase 4 trial is sponsored by GlaxoSmithKline and is currently Not yet recruiting. The study focuses on Pulmonary Disease, Chronic Obstructive. Target enrollment is 460 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GlaxoSmithKline
Timeline & Enrollment
Phase 4
Oct 30, 2022
Nov 30, 2023
Primary Outcome
Change from baseline in COPD Assessment Test (CAT) score
Summary
The primary objective of this study is to evaluate the effectiveness of TRELEGY ELLIPTA on
 health status in participants with symptomatic COPD. The secondary objective is to evaluate
 the effectiveness of TRELEGY ELLIPTA on dyspnea and lung function in participants with
 symptomatic COPD.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05535972
Non-Device Trial